#### 1 vRNA-vRNA interactions in influenza A virus HA vRNA

## 2 packaging

3

	4	Sho	Miyamoto <sup>1,2</sup> ,	Yukiko	Muramoto <sup>1</sup> .	Keiko	Shindo <sup>1,3</sup> ,	Yoko	Fujita <sup>1,</sup>
--	---	-----	---------------------------	--------	-------------------------	-------	-------------------------	------	----------------------

5 Takeshi Morikawa<sup>1,4</sup>, Ryoma Tamura<sup>1,4</sup>, Jamie L Gilmore<sup>1</sup>, Masahiro

6 Nakano<sup>1,4</sup>, Takeshi Noda<sup>1,4\*</sup>

7

8 <sup>1</sup> Laboratory of Ultrastructural Virology, Institute for Frontier Lif	e and
---	-------

9 Medical Sciences, Kyoto University, Kyoto, Japan

10 <sup>2</sup> Department of Molecular Virology, Graduate School of Medicine, Kyoto

- 11 University, Kyoto, Japan
- 12 <sup>3</sup> Keihanshin Consortium for Fostering the Next Generation of Global
- 13 Leaders in Research, Kyoto, Japan
- <sup>4</sup> Laboratory of Ultrastructural Virology, Graduate School of Biostudies,
- 15 Kyoto University, Kyoto, Japan

16

17 \* Corresponding author

## 18 E-mail: t-noda@infront.kyoto-u.ac.jp (TN)

## 20 Abstract

21	The genome of the influenza A virus is composed of eight single-stranded
22	negative-sense RNA segments (vRNAs). The eight different vRNAs are
23	selectively packaged into progeny virions. This process likely involves
24	specific interactions among vRNAs via segment-specific packaging signals
25	located in the 3' and 5' terminal coding regions of vRNAs. To identify
26	vRNA(s) that interact with hemagglutinin (HA) vRNA during genome
27	packaging, we generated a mutant virus, HA 5m2, which possessed five
28	silent mutations in the 5' packaging signal region of HA vRNA. The HA 5m2
29	virus had a specific defect in HA vRNA incorporation, which reduced the
30	viral replication efficiency. After serial passaging in cells, the virus acquired
31	additional mutations in the 5' terminal packaging signal regions of both HA
32	and PB2 vRNAs. These mutations contributed to recovery of viral growth
33	and packaging efficiency of HA vRNA. A direct RNA-RNA interaction
34	between the 5' ends of HA and PB2 vRNAs was confirmed in vitro. Our
35	results indicate that direct interactions of HA vRNA with PB2 vRNA via their
36	packaging signal regions are important for selective genome packaging and

#### 37 enhance our knowledge on the emergence of pandemic influenza viruses

38 through genetic reassortment.

## 39 Introduction

40	The genome of the influenza A virus consists of eight segmented,
41	single-stranded, negative-sense viral RNAs (vRNAs). Each vRNA contains
42	a central coding region in an antisense orientation. This region is flanked
43	by segment-specific noncoding regions and common terminal promoter
44	sequences. Each vRNA forms a helical, rod-shaped ribonucleoprotein
45	complex (vRNP) that associates with multiple nucleoproteins (NPs) and with
46	a heterotrimeric RNA-dependent RNA polymerase complex composed of
47	PB2, PB1, and PA proteins. The vRNP is responsible for transcription and
48	replication of constituent vRNA. Recent studies examining NP-vRNA
49	interactions in the context of vRNPs have shown that the NPs bind to vRNA
50	nucleotides non-uniformly without sequence specificity[1, 2], suggesting
51	that some parts of the vRNAs are free of NPs, and can potentially form
52	secondary or tertiary structures that protrude from the surface of rod-
53	shaped vRNPs.

54 There is evidence to suggest that progeny virions selectively 55 package each copy of the eight vRNAs. In virions, the eight different vRNPs

56 are arranged in a specific '1+7' pattern, where one vRNP is surrounded by 57 the other seven vRNPs[3, 4]. The mechanism by which each copy of the 58 eight vRNAs is selected from a large pool of vRNAs and non-viral RNAs in 59 virus-infected cells, and how these vRNAs are organized into the specific 60 '1+7' arrangement, remains unclear. The segment-specific packaging signal 61 sequences, located in the noncoding and terminal coding regions of both 62 the 3' and 5' ends of each vRNA, likely ensure the integrity of genome 63 packaging[5-10]. The terminal coding regions within these packaging signal 64 sequences are thought to be involved in co-packaging of multiple vRNAs, 65 and are referred to as bundling signals [11]. Mutations or deletions in 66 bundling signal sequences reduce the packaging efficiency of several 67 vRNAs. The impact of such mutations or deletions on packaging efficiency 68 is hierarchical among the eight vRNAs[8, 12-19], suggesting that there are 69 specific interactions among the vRNPs. The vRNPs form sub-bundles en 70 route to the plasma membrane [20, 21], and vRNPs in virions are directly 71 or indirectly interconnected with each other[22, 23]; these findings offer 72 additional evidence for the existence of vRNA-vRNA interactions.

73 То further examine the likely involvement of vRNA-vRNA 74 interactions in genome packaging, it is necessary to identify which vRNA 75 segments interact with one another, and which regions of each vRNA 76 segment participate in these interactions. The potential *in-vitro* interactions 77 of various naked vRNA segments have previously been described in human 78 H3N2 and avian H5N2 viruses [22, 24]. However, the various combinations 79 of vRNA-vRNA interactions differ between the two viruses. It also remains 80 unclear whether such in-vitro vRNA-vRNA interactions in the absence of 81 NPs reflect interactions that may occur among vRNPs in vivo. Only some 82 nucleotides that are important for vRNA-vRNA interactions have been 83 identified in the context of virus replication in cells and co-packaging into virions[22, 25]. These studies suggest that the 5' ends of M vRNA and the 84 85 central coding region of PB1 vRNA are involved in interactions and co-86 packaging with NA vRNA, respectively. In addition, interactions between 87 PB1 and NS vRNAs may also be necessary for efficient viral replication and genome packaging. However, the region in NS vRNA identified to interact 88 with PB1 vRNA is not located in the region of the previously reported 89

90 genome packaging signal [26]. Thus, the role of vRNA-vRNA interactions in91 genome packaging remains unclear.

92	In this study, we used serial passaging to identify which vRNA(s)
93	interact with the hemagglutinin (HA) vRNA packaging signal in selective
94	genome packaging. We first generated a mutant influenza virus (A/WSN/33)
95	that possesses five silent mutations in the packaging signal of HA vRNA,
96	which causes a specific defect in the incorporation of HA vRNA. Then, we
97	serially passaged the mutant virus in cultured cells to restore efficient
98	incorporation of HA vRNA, and identified mutations that had been newly
99	introduced into the vRNAs. In addition, we examined the interactions of HA
100	vRNA with potential partner vRNAs in vitro, and assessed the importance
101	of these vRNA-vRNA interactions in the packaging signal regions specific
102	for HA vRNA incorporation and viral replication.

103

#### 104 **Results**

## 105 Generation of mutant viruses possessing silent mutations in the 106 packaging signal of HA vRNA. 107 We first disrupted the packaging signal sequence of HA vRNA which 108 potentially interacts with other vRNAs during selective genome packaging. 109 For this, we used reverse genetics to generate a series of mutant viruses 110 that possessed five silent mutations in either the 3' or 5' packaging signal 111 region of HA vRNA without any amino acid mutations (Fig 1A). The 112 respective viral titers were examined by plaque assays (Fig 1B). Eight out 113 of nine mutant viruses replicated at a level similar to that of the wild-type 114 virus, showing titers of approximately $3.8 \times 10^8$ PFU/ml; however, an HA 5m2 115 virus, possessing five silent mutations at nucleotides 1664 to 1676 in HA vRNA, exhibited an approximately 87% reduced growth rate compared to 116 117 the wild-type virus. Sequence analysis confirmed that no unexpected 118 mutations occurred in any of the eight vRNAs of the HA 5m2 virus. These 119 results indicate that nucleotides 1664 to 1674 in the packaging signal region 120 of HA vRNA are necessary for efficient virus growth and are likely involved

121 in HA vRNA packaging, which in agreement with results reported by a122 previous study[14].

123

124 Serial passaging of the HA 5m2 virus in cells

125 We hypothesized that after several passages, the HA 5m2 virus 126 would acquire adaptive mutations in vRNAs, which would restore viral 127 fitness. Accordingly, the HA 5m2 virus was serially passaged in Madin-128 Darby Canine Kidney (MDCK) cells, and viral titers were assessed by 129 plaque assay after each passage. The viruses were designated as HA 5m2 130 P1, P2, P3, P4, P5, P6, P7, P8, P9, and P10 viruses, according to the 131 number of passages in MDCK cells. As expected, the growth of the HA 5m2 132 P10 virus was restored to approximately 61% of that shown by the wild-type virus (Fig 2A). The titer of the HA 5m2 P10 virus did not increase with an 133 134 additional 10 passages (data not shown). Sequencing analysis of all eight 135 HA 5m2 P10 virus vRNAs revealed that two mutations were newly 136 introduced into the 5' terminal coding regions of HA vRNA (T1665C) and 137 PB2 vRNA (G2271T); both of these vRNAs are located within the previously

138 identified genome packaging signaling regions [6, 8, 14, 16].

139	To assess whether these two mutations contributed to the growth of
140	the HA 5m2 virus, we used reverse genetics to generate recombinant HA
141	5m2 viruses with additional mutation(s). Recombinant HA 5m2 viruses,
142	which possessed a single mutation in HA T1665C or PB2 G2271T, both
143	showed replication that was partially restored to 11 and 24% of the wild-
144	type virus, respectively (Fig 2B). The recombinant HA 5m2 virus with a
145	double mutation showed replication that was approximately 65% of the wild-
146	type virus, similar to the replication levels of the HA 5m2 P10 virus (Fig 2A
147	and 2B).
147 148	and 2B). The HA T1665C and PB2 G2271T mutations lead to amino acid
148	The HA T1665C and PB2 G2271T mutations lead to amino acid
148 149	The HA T1665C and PB2 G2271T mutations lead to amino acid substitutions HA S545P and PB2 Q748H, respectively. The amino acid 545
148 149 150	The HA T1665C and PB2 G2271T mutations lead to amino acid substitutions HA S545P and PB2 Q748H, respectively. The amino acid 545 is located in the transmembrane region of the HA protein; hence, this
148 149 150 151	The HA T1665C and PB2 G2271T mutations lead to amino acid substitutions HA S545P and PB2 Q748H, respectively. The amino acid 545 is located in the transmembrane region of the HA protein; hence, this substitution may affect intracellular transport to the plasma membrane and

155	in the HA 5m2 P10, HA 5m2 P1, and wild-type virions. This suggests that
156	the S545P substitution has little or no effect on the amount of HA protein
157	incorporated into virions (Fig 2C). To examine the impact of the Q748H
158	substitution on the polymerase activity of the PB2 protein, we used RT-
159	qPCR to quantify the amount of vRNA in virus-infected cells at 7 hours post-
160	infection. The amount of vRNA was similar in HA 5m2 P10-infected, HA 5m2
161	P1-infected, and wild-type virus-infected cells, suggesting that the Q748H
162	substitution in PB2 had little or no effect on polymerase activity (Fig 2D).
163	Taken together, these results suggest that T1665C mutations in HA vRNA
164	and G2271T mutations in PB2 vRNA participate in the restoration of HA 5m2
165	viral replication at the RNA level.
166	
167	Efficiency of packaging eight vRNAs in HA 5m2 viruses
168	Because the HA 5m2 virus possessed five silent mutations in the 5'

Because the HA 5m2 virus possessed five silent mutations in the 5' packaging signal region of HA vRNA, we predicted that it would show defects in the packaging efficiency of vRNAs (especially of HA vRNA). We also expected that additional mutations in the 5' packaging signals of HA

172	and PB2 vRNAs would improve the packaging efficiency of HA vRNA. To
173	assess the packaging efficiency of the HA 5m2 P1 and HA 5m2 P10 viruses,
174	we extracted vRNA from wild-type, HA 5m2 P1, and HA 5m2 P10 viruses;
175	then, we quantified the amount of the eight influenza vRNA segments using
176	RT-qPCR. As expected, the HA 5m2 P1 virus showed a marked defect in
177	the packaging efficiency of HA vRNA; the packaging efficiency was reduced
178	to approximately 24% compared with that of the wild-type virus. The HA 5m2
179	P1 virus also showed small defects in the packaging efficiency of PA, NP,
180	and NA vRNAs (Fig 3A). Importantly, in the HA 5m2 P10 virus, the packaging
181	efficiency of HA vRNA was largely recovered to approximately 72% of that
182	in the wild-type, and those of PA, NP, and NA vRNAs were also partially
183	recovered (Fig 3A).

To further examine the contribution of the PB2 G2271T and HA T1665C mutations to vRNA packaging efficiency, we used RT-qPCR to analyze the amount of packaged vRNA in recombinant HA 5m2 viruses possessing a single mutation or a double mutation. In both recombinant HA 5m2 viruses with either a single PB2 G2271T or HA T1665C mutation, the

189	packaging efficiency of HA vRNA was restored to approximately 33 and 59%
190	to that of the wild-type virus, respectively (Fig 3B). In the recombinant HA
191	5m2 virus possessing the double mutation, the packaging efficiency of HA
192	vRNA was largely restored to approximately 77% of that of the wild-type
193	virus (Fig 3B); this was consistent with the packaging efficiency of HA vRNA $$
194	in the HA 5m2 P10 virus. Taken together, these results show that disruption
195	of the 5' genome packaging signal in HA vRNA reduces the packaging
196	efficiency of HA vRNA. Our results also show that additional mutations in
197	the sequences of 5' genome packaging signals of HA and PB2 vRNAs are
198	required for efficient HA vRNA packaging. This suggests that functional
199	interactions occur between HA and PB2 vRNAs via their 5' genome
200	packaging signals during viral replication.

201

#### 202 Ultrastructural analysis of the HA 5m2 viruses.

To investigate how the RNPs are packaged into the HA 5m2 P1 and HA 5m2 P10 viruses, we examined ultrathin sections via electron microscopy (EM). Representative images of transversely and longitudinally

206	sectioned wild-type, HA 5m2 P1, and HA 5m2 P10 virions, budding from the
207	cell surfaces, are shown in Fig 4A. While some transversely sectioned wild-
208	type and HA 5m2 P10 virions appeared empty, as reported previously [26],
209	almost all longitudinally sectioned wild-type and HA 5m2 P10 virions
210	contained RNPs positioned at the tip of the budding virions. Conversely, the
211	HA 5m2 P1 viruses often possessed empty particles in both transverse and
212	longitudinal sections, suggesting that the HA 5m2 virus had defects in the
213	incorporation of RNPs.
214	To examine the incorporation of RNPs into virions in more detail,
215	we determined the proportion of empty particles in wild-type, HA 5m2 P1,
216	and HA 5m2 P10 viruses. For this, virions were purified by
217	ultracentrifugation through a sucrose cushion and observed by cryo-TEM
218	(Fig 4B). The particles of the wild-type virus mainly showed uniformly
219	spherical shapes of approximately 111 nm in diameter; 0.9% (n=1085) of
220	virions appeared empty or contained only a few vRNPs (Table 1). With a
221	diameter of approximately 87 nm (n=10, $p$ <0.0001), such vRNP packaging-

223	multiple RNPs. The proportion of vRNP packaging-deficient particles in the
224	HA 5m2 P1 virus was 7.0% (n=1401), significantly higher than those of the
225	HA 5m2 P10 (3.2%, n=852, <i>p</i> <0.0001) and wild-type (0.9%, n=1085,
226	p<0.0001) viruses. The results of EM analysis support the notion that
227	potential interactions between the 5' packaging signals of HA and PB2
228	vRNAs are important for appropriate genome packaging.

229

Table 1. Effect of silent mutations and passages on thepackaging of RNPs into progeny virions

	Experiment	t	HA 5m2	HA 5m2
	no.		P1	P10
	1	3 / 341	32 / 505	14 / 370
Droportion of	1	(0.9%)	(6.3%)	(3.7%)
Proportion of	2	7 / 744	66 / 896	13 / 482
vRNP packaging-		(0.9%)	(7.4%)	(2.7%)
deficient particles	Total	10 / 1085	98 / 1401	27 / 852
	TOTAL	(0.9%)	(7.0%)	(3.2%)
p-value*		<0.0001		<0.0001

\*Proportions of vRNP packaging-deficient particles in each virus were
compared with that in the HA 5m2 P1 virus. Data were analyzed using
Dunnett's test.

#### A direct interaction between HA and PB2 vRNA occurs via the 5' ends

#### 235 of packaging signals in vitro

236	We next aimed to confirm that a functional interaction between the
237	5' terminal regions of HA and PB2 vRNAs is involved in efficient packaging
238	of HA vRNA. For this, we used a gel shift assay to examine whether direct
239	RNA-RNA interactions between these two vRNAs occur in vitro. To eliminate
240	possible nonspecific interactions via the non-packaging signal regions of
241	vRNAs, we synthesized a short HA vRNA comprising the 5' noncoding
242	region and the 120-nucleotide long coding region, which is designated as
243	5'HA(120). We also synthesized a short PB2 vRNA comprising the 5'
244	noncoding region and the 300-nucleotide long coding region, which is
245	designated as 5'PB2(300) (Fig 5A). In addition to the 5'HA(120) possessing
246	the wild-type HA vRNA sequence, we synthesized mutant 5'HA(120)
247	sequences into which we introduced five silent mutations corresponding to
248	HA 5m1, HA 5m2, HA 5m3, HA 5m4, and HA 5m5 (Fig 1A); these mutant
249	5'HA(120) vRNAs were designated as 5'HA(120) 5m1, 5'HA(120) 5m2,
250	5'HA(120) 5m3, 5'HA(120) 5m4, and 5'HA(120) 5m5, respectively. The

251	mixture of wild-type 5'HA(120) and 5'PB2(300) showed slower migration of
252	the band, indicating formation of a vRNA-vRNA complex (Figs 5B and 5C).
253	The mutant 5'HA(120) 5m1, 5'HA(120) 5m3, 5'HA(120) 5m4, and 5'HA(120)
254	5m5 vRNAs also formed a complex with 5'PB2(300), whose proportions
255	were 69-95% compared to the complex of 5'HA(120) and 5'PB2(300). These
256	results are consistent with our viral replication data, showing that such
257	mutations in HA vRNA did not markedly affect viral growth (Fig 1B). In
258	contrast, the 5'HA(120) 5m2 vRNA associated with 5'PB2(300) to a lesser
259	degree and did not form a vRNA-vRNA complex efficiently, with only 12%
260	complex formation compared to the 5'HA(120) and 5'PB2(300), correlating
261	with the reduced viral growth of the HA 5m2 virus (Fig 1B). Taken together,
262	these results indicate that there is an interaction between the 5' packaging
263	signals of HA and PB2 vRNAs in the context of vRNPs, which is important
264	for optimal packaging of HA vRNA.
265	

## 266 **Discussion**

267	Specific interactions among eight different vRNAs are likely
268	required for selective genome packaging of the influenza viruses. To identify
269	the interactions of HA vRNA in the context of RNPs, we generated a mutant
270	HA 5m2 virus with reduced packaging efficiency of HA vRNA, and repeatedly
271	passaged this virus in cultured cells to restore viral fitness. We found that
272	the HA 5m2 virus acquired additional mutations in the 5' packaging signal
273	sequences of HA and PB2 vRNAs; this restored HA vRNA packaging
274	efficiency and viral growth. Our results suggest that the packaging signal at
275	the 5' terminal coding region of HA vRNA is involved in co-packaging of the
276	eight different vRNAs; this likely occurs via a direct RNA-RNA interaction
277	with the 5' packaging signal of PB2 vRNA. To the best of our knowledge,
278	this is the first study experimentally showing that a packaging-deficient
279	virus can recover its packaging efficiency by the introduction of mutations
280	in other vRNA segments during viral replication.
281	The 5' packaging signal sequence, located at nucleotides 1662 to

282 1681 in HA vRNA, is more than 90% conserved in H1 subtype influenza

283 viruses. However, neighboring regions the show less sequence 284 conservation [14], suggesting that this region is important for HA vRNA 285 packaging at the RNA level. Our results show that introduction of five silent 286 mutations into the highly conserved region at nucleotides 1664 to 1676 in HA vRNA reduced the incorporation efficiency of HA vRNA (Fig. 2A). An 287 288 additional mutation at nucleotide 1665 restored the reduced efficiency of 289 HA vRNA packaging (Fig. 2B). This confirms that the highly conserved 290 region in the sequence of the 5' terminal packaging signal is involved in 291 incorporation of HA vRNA. Recent findings indicate that NP non-uniformly 292 decorates vRNA [1, 2]. Therefore, it is possible that the region at 293 nucleotides 1664 to 1676 in HA vRNA, identified in this study, is NP-free 294 and forms secondary or tertiary structures on vRNPs to interact with the 5' 295 packaging signal of PB2 vRNA. However, whether the 5' terminal coding 296 region of HA vRNA is a low NP-binding region remains unclear [1, 2]. Additional work is necessary to determine the precise location of the NP-297 298 free region of HA vRNA in the A/WSN/33 strain.

After the HA 5m2 virus was serially passaged in MDCK cells, the

300	virus acquired a G2271T mutation in the 5' packaging signal sequence of
301	PB2 vRNA, which recovered the reduced incorporation of HA vRNA (Fig.
302	2B). This finding suggests that the region around nucleotide 2271 in PB2
303	vRNA is involved in interactions with HA vRNA. However, a previous study
304	showed that the introduction of silent mutations at nucleotides 2268 to 2286,
305	including a mutation at nucleotide 2271, in PB2 vRNA did not reduce the
306	packaging efficiency of HA vRNA [14]. Therefore, it is possible that the
307	mutation at G2271T in PB2 vRNA, found in this study, was acquired for the
308	optimal packaging of HA 5m2 vRNA but not of wild-type HA vRNA.
309	Although the 5' terminal coding region of H1 subtype HA vRNA is
310	conserved in H1 HA vRNA, it is substantially different from other subtypes
311	of HA vRNAs at the nucleotide level [13]. In contrast, the 5' terminal coding
312	region of PB2 vRNA is highly conserved in influenza viruses [13, 17],
313	suggesting that intersegmental interactions between HA and PB2 vRNAs
314	via their 5' terminal regions may be specific to the H1 subtype. Native gel
315	electrophoresis analysis of in-vitro vRNA-vRNA interactions revealed that
316	avian H5N2 and human H3N2 viruses show different intersegmental

317	networks among the eight vRNAs, and do not show strong interactions
318	between HA and PB2 vRNAs [22, 24]. In the context of vRNPs, in-vitro
319	interactions do not necessarily reflect interactions in-vivo. Therefore,
320	further studies are needed to clarify whether HA vRNAs of other subtypes
321	require interactions with PB2 vRNA for HA vRNA packaging in the context
322	of vRNPs.

323 The reduced HA vRNA packaging efficiency of the HA 5m2 virus was 324 rescued when the virus spontaneously acquired adaptive mutations in HA 325 and PB2 vRNAs during serial passaging (Fig. 2A and 2B). Previously, Marsh 326 et al., serially passaged an influenza A virus (WSN strain), which possesses 327 synonymous mutations in HA vRNAs, to determine whether the virus would 328 generate adaptive mutations for recovery of the reduced HA vRNA 329 packaging efficiency. However, the virus did not generate any mutations to 330 improve viral fitness [14]. This may have been due to the number of 331 synonymous mutations introduced into the HA vRNAs. Nine nucleotide 332 mutations were introduced into the region of 1659 to 1673 in the HA vRNAs 333 in the study by Marsh et al., while only five mutations were introduced into

334	the region of 1664 to 1679 in HA vRNAs in our present study. More
335	mutations may cause severe incompatibility in vRNA-vRNA interactions.
336	Even repeated serial passaging may not generate multiple nucleotide
337	changes in HA vRNA and its respective interacting vRNA to restore the HA
338	vRNA packaging efficiency.
339	In conclusion, we have shown that an interaction between HA vRNA
340	and PB2 vRNA via the 5' packaging signals is important for HA vRNA
341	packaging. Our results suggest that HA vRNA is co-packaged with PB2
342	vRNA into virions. These findings will help us understand how reassortant
343	influenza viruses incorporate HA vRNA segments, and how pandemic
344	viruses emerge via genetic reassortment.
345	

## 346 Materials and Methods

347 Cells

348	Human embryonic kidney (293T) cells were maintained in
349	Dulbecco's Modified Eagle Medium (D6046, Sigma) supplemented with 10%
350	fetal bovine serum (FB-1365, Biosera, Chile). Madin-Darby Canine Kidney
351	(MDCK) cells were grown in Minimal Essential Medium (MEM)(11430-030,
352	Gibco) containing 5% newborn calf serum (16010-159, Gibco, New Zealand).
353	Cultures were maintained at $37^{\circ}$ C in a 5% CO <sub>2</sub> atmosphere. The medium
354	used during viral infection of cells was MEM containing 0.3% bovine serum
355	albumin (BSA/MEM).
355 356	albumin (BSA/MEM).
	albumin (BSA/MEM). Construction of the Poll HA plasmid
356	
356 357	Construction of the Poll HA plasmid
356 357 358	Construction of the Poll HA plasmid To generate the Poll HA mutant plasmid, we amplified the Poll-HA

#### 362 Reverse genetics

363	Reverse genetics were performed using Poll plasmids that
364	contained cDNA sequences of the A/WSN/33(H1N1) viral genes; all
365	procedures were conducted as described previously [28]. Briefly, eight Poll
366	plasmids and pCAGGS protein-expression plasmids for PB2, PB1, PA, and
367	NP were mixed with the transfection reagent TransIT-293 (Mirus), and
368	added to 293T cells cultured in BSA/MEM. At 48 hours post-transfection,
369	the cells were treated with 1 $\mu g$ /ml of TPCK-Trypsin for 30 min, centrifuged
370	at 1750 × g for 15 min at 4°C, and the supernatant was harvested and stored
371	at -80°C. To generate mutant viruses, the Poll-HA wt plasmid was replaced
372	with a Poll-HA mutant plasmid. Viral titers were determined by a plaque
373	assay conducted using MDCK cells.
074	

374

#### 375 Virus purification

After collecting the supernatants from virus-infected MDCK cells, each supernatant was clarified by centrifugation at 1750 × g for 15 min at 4°C, followed by another centrifugation at 6700 × g for 30 min at 4°C. To eliminate RNAs outside of the virus particles, the supernatants were treated

with 5 µg/ml RNase A (Nacalai Tesque) for 1 hour at 37°C. Virions in the supernatants were purified by ultracentrifugation through a 30% (w/w) sucrose cushion at 125,000 × g for 2 hours at 4°C. The pellets were then resuspended in phosphate buffered saline (PBS).

384

385 Western blotting

386 MDCK cells were infected with the viruses at a multiplicity of 387 infection (MOI) of 1 on ice for 1 hour. The infected MDCK cells were then 388 cultured in BSA/MEM containing 1 µg /ml TPCK-Trypsin. At 10 hours post-389 infection, the supernatant was harvested and purified as described above. 390 The purified virus was dissolved with an equal volume of 2x Tris-Glycine 391 SDS Sample Buffer (Thermo Fisher Scientific) and boiled for 5 min without 392 a reducing agent, and then subjected to SDS-PAGE. Proteins were 393 electroblotted onto Immobilon-P transfer membranes (Millipore 394 Corporation). The membranes were blocked with Blocking One (Nacalai 395 Tesque) for 30 min at room temperature, and then incubated with goat anti-396 influenza A virus polyclonal antibody (ab20841, Abcam, 1:10,000 dilution) 397 overnight at 4°C. After incubation with rabbit anti-goat IgG secondary
398 antibody (ab6741, Abcam, 1:10,000 dilution) for 1 hour at room temperature,
399 the blots were developed using a Chemi-Lumi One Super (Nacalai Tesque).

400

401 RT-qPCR

402 The packaged vRNAs were extracted from purified viruses using an 403 RNeasy Mini Kit (Qiagen). 100 ng of extracted vRNAs were reverse 404 transcribed Uni-12 (5'-AGCRAAAGCAGG-3') using primer and а 405 Superscript III reverse transcriptase (Invitrogen). Quantification was 406 performed by qPCR on a Rotor-Gene Q 2plex System (Qiagen) using 407 segment-specific primers modified from the protocol by Marsh et al. The 408 primers used are listed in S1 Table. For each sample, reactions contained 409 1 µl 10-fold diluted RT product, 7.5 µl THUNDERBIRD SYBR gPCR Mix 410 (Toyobo), 0.25  $\mu$ M segment-specific primers, for a final volume of 15  $\mu$ L. 411 Cycling conditions were: 2 min at 94°C, followed by 40 cycles (98°C for 10 412 s, 55°C for 15 s, and 72°C for 30 s).

413 In Figure 2D, total RNA was extracted from virus-infected cells

414 using an RNeasy Mini Kit (Qiagen). For PB2, PB1, HA, and NP vRNAs, RTqPCR was performed as described above, using 100 ng total RNA. The 415 416 values were expressed as numbers of RNA copies in an infected cell, 417 assuming that a cell contained 10 pg of RNA [29, 30]. 418 419 Ultrathin section electron microscopy (EM) 420 Ultrathin section EM was performed as described previously [3]. 421 MDCK cells were infected at MOI=10. At 10 hours post-infection, the 422 infected cells were prefixed with 2.5% glutaraldehyde in 0.1 M cacodylate 423 buffer (pH 7.4) on ice. Ultrathin (50-nm-thick) sections were stained with 2% 424 uranyl acetate in 70% ethanol and in Reynold's lead citrate. Representative 425 images were acquired using HT7700 (Hitachi). 426 427 Quantification of vRNP packaging-deficient particles 428 Purified viruses were applied onto C-flat holey carbon grids 429 (Protichips), which were blotted on a Vitrobot Mark IV (Thermo Fisher

430 Scientific) before plunge-freezing in liquid ethane. Samples were kept cool

431	in liquid nitrogen. Samples were imaged at 200 kV on a Talos F200C
432	(Thermo Fisher Scientific) equipped with a Ceta 16M CMOS camera (Gatan).
433	More than 300 particles were observed for each experiment.
434	
435	<i>In vitro</i> RNA synthesis
436	Shortened HA and PB2 vRNAs were synthesized in vitro using T7
437	transcription as described previously [30]. Briefly, templates containing a
438	T7 phage promoter sequence (5'-TAATACGACTCACTATAGGG-3') were
439	amplified by PCR using corresponding primer pairs and were purified with
440	a QIAquick PCR purification kit (Qiagen). The primers used are listed in S1
441	Table. Purified PCR products were transcribed in vitro using the RiboMAX
442	Large Scale RNA Production System-T7 (Promega) at 37°C for 4 h, followed
443	by RQ1 DNase I (Promega) digestion of the DNA template at $37^{\circ}$ C for 15
444	min. The transcript was purified with an RNeasy Mini Kit.
445	
446	RNA binding assay

447 RNA-RNA interactions were analyzed by electrophoretic mobility

448 shift assays essentially as described previously [24]. To facilitate RNA 449 folding, adjustments were made to the reaction buffer employed and 450 incubation time as described below [31]. Pairs of purified vRNAs (2 pmol of 451 each vRNA) were denatured for 10 min at 65°C in 5 µl of ultrapure water 452 and cooled on ice. We then added 5 µl of 2-fold concentrated buffer (final 453 concentration: 50 mM HEPES, 50 mM KCl, and 20 mM MgCl<sub>2</sub>) and incubated the samples for 2 hours at 37°C. Then, 2  $\mu$ l of loading buffer [40% (v/v) 454 455 glycerol and 0.05% (w/v) bromophenol blue] was added to the samples, and 456 the samples were analyzed using 1.0% agarose gels containing 0.01% (w/v) 457 ethidium bromide. Native gel electrophoresis of the RNA complexes was 458 performed at 4°C in a buffer containing 50 mM Tris, 44.5 mM borate, and 459 0.1 mM MgCl<sub>2</sub>. We then determined the RNA weight fraction (%) of each 460 band in each lane. The percentage of intermolecular complex formation was 461 determined by dividing the weight fraction of a band by the sum of weight 462 fractions in the corresponding lane.

463

#### 464 Statistical analysis

465	The statistical significance of the viral titers, the proportions of
466	vRNP packaging-deficient particles and the formation efficiencies of vRNA-
467	vRNA complexes were calculated using Dunnett's test. Diameters of virus
468	particles observed by EM were statistically analyzed using Welch's t-test. P
469	values of < 0.01 were considered significant.
470	

## 471 Acknowledgments

472 We thank Connor Park for editing the manuscript.

## **References**

475	1. Williams GD, Townsend D, Wylie KM, Kim PJ, Amarasinghe GK,
476	Kutluay SB, et al. Nucleotide resolution mapping of influenza A virus
477	nucleoprotein-RNA interactions reveals RNA features required for
478	replication. Nature communications. 2018;9(1):465. Epub 2018/02/02. doi:
479	10.1038/s41467-018-02886-w. PubMed PMID: 29386621; PubMed Central
480	PMCID: PMCPMC5792457.
481	2. Lee N, Le Sage V, Nanni AV, Snyder DJ, Cooper VS, Lakdawala SS.
482	Genome-wide analysis of influenza viral RNA and nucleoprotein association.
483	Nucleic acids research. 2017;45(15):8968-77. doi: 10.1093/nar/gkx584.
484	3. Noda T, Sagara H, Yen A, Takada A, Kida H, Cheng RH, et al.
485	Architecture of ribonucleoprotein complexes in influenza A virus particles.
486	Nature. 2006;439(7075):490-2. Epub 2006/01/27. doi:
487	10.1038/nature04378. PubMed PMID: 16437116.
488	4. Chou YY, Vafabakhsh R, Doganay S, Gao Q, Ha T, Palese P. One
489	influenza virus particle packages eight unique viral RNAs as shown by FISH
490	analysis. Proceedings of the National Academy of Sciences of the United

491 States of America. 2012;109(23):9101-6. Epub 2012/05/02. doi:
492 10.1073/pnas.1206069109. PubMed PMID: 22547828; PubMed Central
493 PMCID: PMCPMC3384215.

494 5. Fujii Y, Goto H, Watanabe T, Yoshida T, Kawaoka Y. Selective 495 incorporation of influenza virus RNA segments into virions. Proceedings of 496 the National Academy of Sciences of the United States of America. 497 2003;100(4):2002-7. Epub 2003/02/08. doi: 10.1073/pnas.0437772100. PubMed PMID: 12574509; PubMed Central PMCID: PMCPMC149948. 498 499 6. Watanabe T, Watanabe S, Noda T, Fujii Y, Kawaoka Y. Exploitation 500 of nucleic acid packaging signals to generate a novel influenza virus-based 501 stably expressing two foreign genes. Journal of virology. vector 502 2003;77(19):10575-83. Epub 2003/09/13. PubMed PMID: 12970442: 503 PubMed Central PMCID: PMCPMC228515.

Fujii K, Fujii Y, Noda T, Muramoto Y, Watanabe T, Takada A, et al.
Importance of both the coding and the segment-specific noncoding regions
of the influenza A virus NS segment for its efficient incorporation into virions.
Journal of virology. 2005;79(6):3766-74. Epub 2005/02/26. doi:

508 10.1128/jvi.79.6.3766-3774.2005. PubMed PMID: 15731270; PubMed 509 Central PMCID: PMCPMC1075679.

510 8. Muramoto Y, Takada A, Fujii K, Noda T, Iwatsuki-Horimoto K, Watanabe S, et al. Hierarchy among viral RNA (vRNA) segments in their 511 512 role in vRNA incorporation into influenza A virions. Journal of virology. 513 2006;80(5):2318-25. Epub 2006/02/14. 10.1128/jvi.80.5.2318doi: 514 2325.2006. PubMed PMID: 16474138; PubMed Central PMCID: 515 PMCPMC1395381.

9. Ozawa M, Fujii K, Muramoto Y, Yamada S, Yamayoshi S, Takada A,
 et al. Contributions of two nuclear localization signals of influenza A virus
 nucleoprotein to viral replication. Journal of virology. 2007;81(1):30-41.
 Epub 2006/10/20. doi: 10.1128/jvi.01434-06. PubMed PMID: 17050598;
 PubMed Central PMCID: PMCPMC1797272.

521 10. Ozawa M, Maeda J, Iwatsuki-Horimoto K, Watanabe S, Goto H,
522 Horimoto T, et al. Nucleotide sequence requirements at the 5' end of the
523 influenza A virus M RNA segment for efficient virus replication. Journal of
524 virology. 2009;83(7):3384-8. Epub 2009/01/23. doi: 10.1128/jvi.02513-08.

525 PubMed PMID: 19158245; PubMed Central PMCID: PMCPMC2655591.

526	11. Goto H, Muramoto Y, Noda T, Kawaoka Y. The genome-packaging
527	signal of the influenza A virus genome comprises a genome incorporation
528	signal and a genome-bundling signal. Journal of virology.
529	2013;87(21):11316-22. Epub 2013/08/09. doi: 10.1128/jvi.01301-13.
530	PubMed PMID: 23926345; PubMed Central PMCID: PMCPMC3807325.
531	12. Liang Y, Hong Y, Parslow TG. cis-Acting packaging signals in the
532	influenza virus PB1, PB2, and PA genomic RNA segments. Journal of
533	virology. 2005;79(16):10348-55. Epub 2005/07/30. doi:
534	10.1128/jvi.79.16.10348-10355.2005. PubMed PMID: 16051827; PubMed
535	Central PMCID: PMCPMC1182667.
536	13. Gog JR, Afonso Edos S, Dalton RM, Leclercq I, Tiley L, Elton D, et
537	al. Codon conservation in the influenza A virus genome defines RNA
538	packaging signals. Nucleic acids research. 2007;35(6):1897-907. Epub

- 539 2007/03/03. doi: 10.1093/nar/gkm087. PubMed PMID: 17332012; PubMed
- 540 Central PMCID: PMCPMC1874621.
- 541 14. Marsh GA, Hatami R, Palese P. Specific residues of the influenza A

542 virus hemagglutinin viral RNA are important for efficient packaging into 543 budding virions. Journal of virology. 2007;81(18):9727-36. Epub 2007/07/20. 544 doi: 10.1128/jvi.01144-07. PubMed PMID: 17634232; PubMed Central 545 PMCID: PMCPMC2045411. 546 15. Hutchinson EC, Curran MD, Read EK, Gog JR, Digard P. Mutational 547 analysis of cis-acting RNA signals in segment 7 of influenza A virus. Journal 2008;82(23):11869-79. 548 of virology. Epub 2008/09/26. doi: 549 10.1128/jvi.01634-08. PubMed PMID: 18815307; PubMed Central PMCID: 550 PMCPMC2583641. 551 16. Liang Y, Huang T, Ly H, Parslow TG, Liang Y. Mutational analyses 552 of packaging signals in influenza virus PA, PB1, and PB2 genomic RNA segments. Journal of virology. 2008;82(1):229-36. Epub 2007/10/26. doi: 553

554 10.1128/jvi.01541-07. PubMed PMID: 17959657; PubMed Central PMCID:
555 PMCPMC2224372.

556 17. Marsh GA, Rabadan R, Levine AJ, Palese P. Highly conserved 557 regions of influenza a virus polymerase gene segments are critical for 558 efficient viral RNA packaging. Journal of virology. 2008;82(5):2295-304.

559 Epub 2007/12/21. doi: 10.1128/jvi.02267-07. PubMed PMID: 18094182;

560 PubMed Central PMCID: PMCPMC2258914.

- 561 18. Hutchinson EC, Wise HM, Kudryavtseva K, Curran MD, Digard P.
- 562 Characterisation of influenza A viruses with mutations in segment 5
- 563 packaging signals. Vaccine. 2009;27(45):6270-5. Epub 2009/10/21. doi:

564 10.1016/j.vaccine.2009.05.053. PubMed PMID: 19840659; PubMed Central

565 PMCID: PMCPMC2771075.

566 19. Gao Q, Chou YY, Doganay S, Vafabakhsh R, Ha T, Palese P. The
567 influenza A virus PB2, PA, NP, and M segments play a pivotal role during
568 genome packaging. Journal of virology. 2012;86(13):7043-51. Epub
569 2012/04/26. doi: 10.1128/jvi.00662-12. PubMed PMID: 22532680; PubMed
570 Central PMCID: PMCPMC3416350.

571 20. Chou YY, Heaton NS, Gao Q, Palese P, Singer RH, Lionnet T. 572 Colocalization of different influenza viral RNA segments in the cytoplasm 573 before viral budding as shown by single-molecule sensitivity FISH analysis. 574 2013;9(5):e1003358. PLoS pathogens. Epub 2013/05/15. doi: 575 10.1371/journal.ppat.1003358. PubMed PMID: 23671419; PubMed Central

576 PMCID: PMCPMC3649991.

577	21. Lakdawala SS, Wu Y, Wawrzusin P, Kabat J, Broadbent AJ,
578	Lamirande EW, et al. Influenza a virus assembly intermediates fuse in the
579	cytoplasm. PLoS pathogens. 2014;10(3):e1003971. Epub 2014/03/08. doi:
580	10.1371/journal.ppat.1003971. PubMed PMID: 24603687; PubMed Central
581	PMCID: PMCPMC3946384.
582	22. Fournier E, Moules V, Essere B, Paillart JC, Sirbat JD, Isel C, et al.
583	A supramolecular assembly formed by influenza A virus genomic RNA
584	segments. Nucleic acids research. 2012;40(5):2197-209. Epub 2011/11/15.
585	doi: 10.1093/nar/gkr985. PubMed PMID: 22075989; PubMed Central
586	PMCID: PMCPMC3300030.
587	23. Noda T, Sugita Y, Aoyama K, Hirase A, Kawakami E, Miyazawa A,
588	et al. Three-dimensional analysis of ribonucleoprotein complexes in
589	influenza A virus. Nature communications. 2012;3:639. Epub 2012/01/26.
590	doi: 10.1038/ncomms1647. PubMed PMID: 22273677; PubMed Central
591	PMCID: PMCPMC3272569.
592	24. Gavazzi C, Isel C, Fournier E, Moules V, Cavalier A, Thomas D, et

al. An in vitro network of intermolecular interactions between viral RNA 593 594 segments of an avian H5N2 influenza A virus: comparison with a human 595 H3N2 virus. Nucleic acids research. 2013;41(2):1241-54. Epub 2012/12/12. doi: 10.1093/nar/gks1181. PubMed PMID: 23221636; PubMed Central 596 597 PMCID: PMCPMC3553942. 598 25. Gilbertson B, Zheng T, Gerber M, Printz-Schweigert A, Ong C, 599 Marguet R, et al. Influenza NA and PB1 Gene Segments Interact during the 600 Formation of Viral Progeny: Localization of the Binding Region within the 601 PB1 Gene. Viruses. 2016;8(8). Epub 2016/08/25. doi: 10.3390/v8080238. PubMed PMID: 27556479; PubMed Central PMCID: PMCPMC4997600. 602 603 26. Gavazzi C, Yver M, Isel C, Smyth RP, Rosa-Calatrava M, Lina B, et 604 al. A functional sequence-specific interaction between influenza A virus 605 genomic RNA segments. Proceedings of the National Academy of Sciences 606 of the United States of America. 2013;110(41):16604-9. Epub 2013/09/27. 607 doi: 10.1073/pnas.1314419110. PubMed PMID: 24067651; PubMed Central 608 PMCID: PMCPMC3799358.

40


Ochman H, Gerber AS, Hartl DL. Genetic applications of an inverse

609

27.

610	polymerase chain reaction. Genetics. 1988;120(3):621-3. Epub 1988/11/01.
611	PubMed PMID: 2852134; PubMed Central PMCID: PMCPMC1203539.
612	28. Neumann G, Watanabe T, Ito H, Watanabe S, Goto H, Gao P, et al.
613	Generation of influenza A viruses entirely from cloned cDNAs. Proceedings
614	of the National Academy of Sciences of the United States of America.
615	1999;96(16):9345-50. Epub 1999/08/04. PubMed PMID: 10430945; PubMed
616	Central PMCID: PMCPMC17785.
617	29. Hatada E, Hasegawa M, Mukaigawa J, Shimizu K, Fukuda R.
618	Control of Influenza Virus Gene Expression: Quantitative Analysis of Each
619	Viral RNA Species in Infected Cells. The Journal of Biochemistry.
620	1989;105(4):537-46.
621	30. Kawakami E, Watanabe T, Fujii K, Goto H, Watanabe S, Noda T, et
622	al. Strand-specific real-time RT-PCR for distinguishing influenza vRNA,
623	cRNA, and mRNA. Journal of virological methods. 2011;173(1):1-6. Epub
624	2010/12/28. doi: 10.1016/j.jviromet.2010.12.014. PubMed PMID: 21185869;
625	PubMed Central PMCID: PMCPMC3049850.
626	31. Buchmueller KL, Weeks KM. Tris-borate is a poor counterion for

- 627 RNA: a cautionary tale for RNA folding studies. Nucleic acids research.
- 628 2004;32(22):e184. Epub 2004/12/17. doi: 10.1093/nar/gnh182. PubMed
- 629 PMID: 15601995; PubMed Central PMCID: PMCPMC545480.








Fig 1. Generation of mutant influenza A viruses by reverse genetics and replication efficiencies of these mutant viruses. (A) Schematic diagram of mutant HA vRNAs with silent mutations introduced into the packaging signal sequences. The 3' and 5' ends of the HA coding region (nucleotides 33–98 and 1649–1730, respectively) are shown in the mRNA-sense orientation. (B) 293T cells were transfected with plasmids to produce the mutant and wild-type viruses. MDCK cells were infected with these mutant and wild-type viruses at a multiplicity of infection (MOI) of 10<sup>-5</sup>. Virus yields at 48 h post-infection were determined by a plaque assay on MDCK cells. The data represent the mean  $\pm$  SD (n = 3). Dunnett's test; \*P < 0.01

# Figure 1



А.


C.




**Fig 2. Analysis of HA 5m2 viral replication.** (A) The HA 5m2 virus was passaged in MDCK cells at an MOI of  $10^{-5}$ . For each passage, supernatants were collected at 48 hours post-infection, and viral yields were determined by a plaque assay on MDCK cells. (B) 293T cells were transfected with plasmids to produce the mutant HA5m2 and wild-type viruses. After infecting MDCK cells at an MOI of  $10^{-5}$ , viral yields were determined at 48 hours post-infection. The data represent the mean  $\pm$  SD (n = 3). (C) The purified viruses were analyzed via western blot using an anti-influenza A virus polyclonal antibody against HA, NP, and M1. (D) MDCK cells were infected with the viruses at an MOI of 1. Total RNA was extracted at 7 hours post-infection. PB2, PB1, HA, and NP vRNAs were analyzed using RT-qPCR analysis. Data represent the mean  $\pm$ SD of two independent experiments, each performed in triplicate.

bioRxiv preprint doi: https://doi.org/10.1101/2020.01.15.907295; this version posted January 16, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

A.








**Fig 3**. **Packaging of individual vRNA segments into progeny viral particles.** The amount of vRNA extracted from purified virus particles was quantified by RT-qPCR. All vRNAs were normalized to the amount of PB1 vRNA and to the average of that contained in the wild-type virus. Data represent the mean ±SD from two independent experiments each conducted in triplicate. (A) The panel shows the relative amounts of eight vRNA from the wild-type virus, HA 5m2 P10 virus, and HA 5m2 P1 virus. (B) The panel shows the relative amounts of eight vRNA from the wild-type virus of eight vRNA from the wild-type virus and mutant HA 5m2 viruses.

A. HA wt

## HA 5m2 P1







HA 5m2 P10

HA wt

Β.

HA 5m2 P1

**Fig 4. Morphology of HA 5m2 P1, HA5m2 P10, and wild-type viruses**. (A) Ultrathin sections of viral particles budding from infected MDCK cells were observed using transverse section (upper side) and longitudinal section (lower side). Empty particles are indicated by arrowheads. Bars, 200 nm. (B) Purified virus particles were observed by cryo-TEM. Empty particles are indicated by arrowheads. Bars, 100 nm.

# Figure 4




Fig 5. Gel shift assay using 5' end sequences of HA and PB2 vRNAs. (A) Schematic representation of 5'HA(120) and 5'PB2(300) vRNAs. The solid line represents the noncoding regions of vRNAs at the 3' and 5' ends. The white box represents the coding regions of the HA or PB2 proteins. The dashed line represents the deleted regions. 5'HA(120) and 5'PB2(300) contain 120 or 300 nucleotides in the coding and noncoding regions at their 5' ends, respectively. (B) The effect of silent mutations in 5'HA(120) vRNA on binding to 5'PB2(300) vRNA. 5'PB2(300) vRNA was incubated with wild-type and mutated 5'HA(120) vRNAs as indicated at the top of the gel image. Individual vRNA bands and vRNA complexes are indicated on the right. (C) Quantification of 5'HA(120)-5' PB2(300) complexes for each lane. The relative band intensity of the complex is indicated in comparison to that of the wild-type. The data represent the mean  $\pm$  SD (n = 3). Dunnett's test; \*P < 0.01; \*\*P < 0.001.